Gross-To-Net FOMO:
What GTN Dangers Are You Missing Post-Launch?
Join Us Live | June 17, 2026 | 12 PM EST
Uncover the Hidden GTN Risks Impacting Your Bottom Line
What You Don't Know About GTN Pressures Could Be Costing You Millions
Gross-to-net (GTN) planning doesn’t end at launch—it evolves. While pre-launch strategies account for rebates, distribution fees, and payer contracts, the real challenges emerge post-launch. Incognito accumulators & maximizers, pharmacy economics, and unexpected claim behaviors can quietly erode your program dollars, leaving you accountable for losses you couldn’t predict.
In this webinar, we’ll explore:
- The evolving dynamics of GTN pressures post-launch
- How accumulators, maximizers, and pharmacy economics impact your copay funds
- Strategies to identify and mitigate risks before they affect your bottom line
Join us live (or watch the playback) to gain actionable insights and learn how to govern your copay programs. Register today!
Secure Your Spot—Protect Your Copay Funds
SVP, Market Development, ConnectiveRx
In his more than 25-year career, Chris has become a recognized voice in the patient affordability and specialty medication arena, pioneering prominent copay and patient affordability programs, and creating innovative solutions for his clients.
A recognized leader in the space, Dowd has been on the forefront of virtually every development in the patient copay industry over the past decade.
Chris leads strategic market analysis and product go-to-market strategies at ConnectiveRx.